Qualissima associates a big talented variety: experience, versatility and complementarity insure a control of the projects management.
Olivier BLIN is a Professor of Universities – Hospital Practitioner, Clinical Pharmacologist and neuropsychiatrist. He is in charge of the Center of Clinical Pharmacology and Therapeutic Evaluations in Assistance-Publique-Hôpitaux of Marseille. He is also responsible for the Team Pharmacology and Physiopathology of the Feelings within the " Institute of the Cognitive Neurosciences of the Mediterranean , UMR CNRS 6193". Olivier Blin a is member of the American Society for Clinical Pharmacology and Therapeutics and of the American College of Clinical Pharmacology, past-president of the French Association of Biological Psychiatry, Secretary of the Clinical Pharmacology Section of the French Society of Pharmacology and Therapeutics. QUALISSIMA is the valorisation company of Olivier BLIN. It is the scientific consultant.
Sophie TARDIEU is a pharmacist, former resident of Hospitals and Hospital Practitioner in Public health. She brings her methodological support in the field of the pharmaco epidemiology and of the medical evaluation. She is a member of the French Society of Pharmacology and Therapeutics. She is a co-founder of QUALISSIMA.
Séverine PITEL has got a PhD in sciences. After a thesis on the clinical development of a therapeutic innovative, she joined QUALISSIMA in November, 2007 as attached scientist. She participates in the coordination of the clinical studies and the medical writing. She also participates in the constitution of clinical trial authorization dossiers in the field of medicines and medical devices.
Romain COMBALAT has got a Master in Sciences. After getting a Diploma of Training of the Investigators in Clinical trials ( DIU-FIEC), he joined QUALISSIMA in September, 2008 as Clinical Research Associate. He participates in the update of the Standard Operating Procedures, in the organization and the follow-up of clinical trials, and also participates in the constitution of clinical trial authorization dossiers.
